A

American Research Corporation at the Texas Liver Institute | San Antonio, TX

Research site
(Unclaimed)
Location
607 Camden Street, San Antonio, Texas, United States of America
Site insights

Top conditions

Non-alcoholic Fatty Liver Disease (11 trials)

Fatty Liver (10 trials)

Liver Diseases (8 trials)

Biliary Liver Cirrhosis (5 trials)

Cholangitis (5 trials)

Top treatments

Cilofexor
BI 685509
Firsocostat
Obeticholic Acid
UDCA
Pilocarpine
EYE103
ADX-914
PF-06865571
BZF

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

8 of 27
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD) (AMARONE)

EYE103-101 is a 2-part study assessing safety and preliminary efficacy of EYE103 in patients with diabetic macular edema (DME) given as monotherapy o...

Enrolling
Diabetic Macular Edema (DME)
Neovascular Age-related Macular Degeneration (NVAMD)
Drug: EYE103

This study is open to adults with overweight or obesity who also have fatty liver disease. The purpose of this study is to find the highest dose of B...

Enrolling
Obesity
Non-alcoholic Fatty Liver Disease
Drug: Placebo matching BI 3006337
Drug: BI 3006337

This study is open to adults with liver cirrhosis and high blood pressure in the portal vein (main vessel going to the liver). The purpose of this st...

Active, not recruiting
Hypertension, Portal
Drug: Placebo matching Avenciguat (BI 685509)
Drug: Avenciguat (BI 685509)

The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar: An Open-Label Study Following Oral Dosing of Seladelpar to Subjects with Prim...

Enrolling
Hepatic Impairment
Compensated Cirrhosis
Drug: Seladelpar 10 mg or less
Drug: Seladelpar 10 mg

This is a Phase IIa, Randomized, Double-blind, Placebo-controlled, multi-center Proof-of-Concept (POC) Trial in subjects with severe Alopecia Areata.

Enrolling
Alopecia Areata
Drug: ADX-914
Drug: Placebo

An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)

Enrolling
Primary Biliary Cirrhosis
Drug: Seladelpar 5 mg Capsule
Drug: Seladelpar 10 mg Capsule

Study to determine the effect of the investigational drug bezafibrate (BZF) alone and in combination with the investigational drug obeticholic acid (...

Active, not recruiting
Primary Biliary Cholangitis
Drug: Bezafibrate 100 mg
Drug: Bezafibrate Placebo

The goals of this clinical study are to learn more about the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firso...

Active, not recruiting
Nonalcoholic Steatohepatitis
Drug: PTM CILO/FIR
Drug: Cilofexor (CILO)/Firsocostat (FIR)

Trial sponsors

Boehringer Ingelheim logo

Boehringer Ingelheim (6 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems